eFoodSafety.com Inc. Reports to Shareholders that Thailand Declares Bird Flu a National Threat; One-Third of Thailand Declared Disaster Zone to Fight Bird Flu

Business Wire, August 28, 2006

SCOTTSDALE, Ariz. -- Patricia Gruden, president/CEO of eFoodSafety.com Inc. (OTCBB: EFSF), reported today that one-third of Thailand, including Bangkok, has been declared a disaster zone in an effort to help local officials battle bird flu. Most of these provinces are in central and northeastern Thailand.

Thailand has slaughtered more than 300,000 birds since two bird flu outbreaks were detected last month. Thailand's Deputy Prime Minister Chidchai Vanasathidya, at a meeting of some 260 local officials, stated that, "Bird Flu is a national threat. If we fail to contain the outbreak of bird flu, it could spell disaster for our country."

A member of the company's board of directors has hand-delivered samples of the company's products for testing to the National Center for Genetic Engineering and Biotechnology (BIOTEC), a branch of the National Science and Technology Development Agency (NSTDA) located in the greater Bangkok metropolitan area. Subsequent meetings with BIOTEC have confirmed that initial test results on the various products have been very favorable and should lead the way for more specialized and live testing.

"eFoodSafety.com Inc. is and has been working for nearly two months with some of the most noteworthy individuals and groups in Thailand to help contain and combat this deadly disease," stated Gruden.

About eFoodSafety.com Inc.

eFoodSafety.com Inc. is dedicated to improving health conditions around the world through its innovative technologies. The company's Knock-Out Technologies, Ltd. subsidiary has developed an environmentally safe sporicidal product formulated entirely of food-grade components that eradicates anthrax and a germicidal product, Citroxin (formerly named Big Six Plus) -- EPA Reg. No. 82723-1 that kills six major bacteria: E-coli, Listeria, Pseudomonas, Salmonella, Staphylococcus, and Streptococcus, Avian Influenza, and Black Mold. The sporicidal product has completed its final efficacy laboratory study requisite for EPA registration. In the study, it eradicated both Clostridium Sporogenes and Bacillus Subtilis with 100% efficacy on both hard and porous surfaces. The company's MedElite Inc. subsidiary distributes clinically proven products to physicians who then prescribe the products for their patients. It is the exclusive U.S. and worldwide distributor of the Talsyn(TM)-CI/bid Scar Cream that has been clinically proven to facilitate and improve the appearance, redness and strength of scars (www.talsyn.com). The company is also is a distributor for Cinnergen(TM), a non-prescription liquid whole food nutritional supplement that promotes healthy glucose metabolism (www.cinnergen.com), and Trimmendous(TM), a weight loss formula focusing on the body's 24-hour metabolic processes. The company has recently entered into a joint venture agreement with CK41 Direct Inc. to launch an anti-acne skin care system, with a branded name and celebrity spokesperson to-be-announced in the near future.

Please visit the company's Web site at: http://www.efoodsafety.com.

Safe Harbor Forward-Looking Statements

Statements contained in this release that are not strictly historical are "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933 as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements are made based on information available as of the date hereof, and the company assumes no obligation to update such forward-looking statements. Editors and investors are cautioned that such forward-looking statements involve risks and uncertainties and the company's actual results may differ from these forward-looking statements. Such risks and uncertainties include but are not limited to demand for the company's products and services, our ability to continue to develop markets, general economic conditions, our ability to secure additional financing for the company and other factors that may be more fully described in reports to shareholders and periodic filings with the Securities and Exchange Commission.